Amol Akhade

Amol Akhade: BREAKING from China – HER2+ Bladder Cancer may have a new contender

Amol Akhade, Consultant Medical Oncologist at the Suyog Cancer Clinics, posted on X:

“BREAKING from China
HER2+ Bladder Cancer may have a new contender!
DV (Disitamab Vedotin) + Toripalimab
– Met BOTH primary endpoints:
OS
PFS
– Statistically significant
– Clinically meaningful benefit
– Works across HER2 levels (IHC 1+, 2+, 3+)
– Safe in cisplatin-unfit patients
– Manageable safety profile
484 patients | 74 centers | Phase 3 | RC48-C016
Full data at international meetings in 2025!
BLA filing coming soon.
After EV + Pembro set a new bar, DV + Tori may raise it further for HER2+ mUC.”

Bladder Cancer

More posts featuring Amol Akhade on OncoDaily.

Amol Akhade bladder cancer cancer disitamab vedotin HER2+ Bladder Cancer OncoDaily Oncology toripalimab